David Lubner

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. Mr. Lubner served as executive vice president and chief financial officer of Ra Pharmaceuticals, Inc. (Nasdaq: RARX) until May 2020 following its acquisition by UCB S.A. Prior to Ra Pharma, he was senior vice president and chief financial officer of Tetraphase Pharmaceuticals and was previously chief financial officer of PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company until it was acquired by IMS Health in 2015. He was also chief financial officer at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered.